243 related articles for article (PubMed ID: 21144000)
41. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
[TBL] [Abstract][Full Text] [Related]
42. Crystal structure-based comparison of two NAMPT inhibitors.
Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
[TBL] [Abstract][Full Text] [Related]
43. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
Nahimana A; Attinger A; Aubry D; Greaney P; Ireson C; Thougaard AV; Tjørnelund J; Dawson KM; Dupuis M; Duchosal MA
Blood; 2009 Apr; 113(14):3276-86. PubMed ID: 19196867
[TBL] [Abstract][Full Text] [Related]
44. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
45. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase.
Burgos ES; Schramm VL
Biochemistry; 2008 Oct; 47(42):11086-96. PubMed ID: 18823127
[TBL] [Abstract][Full Text] [Related]
46. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
47. Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions.
Maldi E; Travelli C; Caldarelli A; Agazzone N; Cintura S; Galli U; Scatolini M; Ostano P; Miglino B; Chiorino G; Boldorini R; Genazzani AA
Pigment Cell Melanoma Res; 2013 Jan; 26(1):144-6. PubMed ID: 23051650
[No Abstract] [Full Text] [Related]
48. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Bajrami I; Kigozi A; Van Weverwijk A; Brough R; Frankum J; Lord CJ; Ashworth A
EMBO Mol Med; 2012 Oct; 4(10):1087-96. PubMed ID: 22933245
[TBL] [Abstract][Full Text] [Related]
49. Identification of novel Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitors using computational approaches.
Kesherwani M; Raghavan S; Gunasekaran K; Velmurugan D
J Biomol Struct Dyn; 2018 Apr; 36(5):1306-1328. PubMed ID: 28514875
[TBL] [Abstract][Full Text] [Related]
50. Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity.
Jacques C; Holzenberger M; Mladenovic Z; Salvat C; Pecchi E; Berenbaum F; Gosset M
J Biol Chem; 2012 Apr; 287(18):15100-8. PubMed ID: 22399297
[TBL] [Abstract][Full Text] [Related]
51. Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors.
Wilsbacher JL; Cheng M; Cheng D; Trammell SAJ; Shi Y; Guo J; Koeniger SL; Kovar PJ; He Y; Selvaraju S; Heyman HR; Sorensen BK; Clark RF; Hansen TM; Longenecker KL; Raich D; Korepanova AV; Cepa S; Towne DL; Abraham VC; Tang H; Richardson PL; McLoughlin SM; Badagnani I; Curtin ML; Michaelides MR; Maag D; Buchanan FG; Chiang GG; Gao W; Rosenberg SH; Brenner C; Tse C
Mol Cancer Ther; 2017 Jul; 16(7):1236-1245. PubMed ID: 28468779
[TBL] [Abstract][Full Text] [Related]
52. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
[TBL] [Abstract][Full Text] [Related]
53. Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors.
Tanuma SI; Katsuragi K; Oyama T; Yoshimori A; Shibasaki Y; Asawa Y; Yamazaki H; Makino K; Okazawa M; Ogino Y; Sakamoto Y; Nomura M; Sato A; Abe H; Nakamura H; Takahashi H; Tanuma N; Uchiumi F
Molecules; 2020 Aug; 25(16):. PubMed ID: 32785052
[TBL] [Abstract][Full Text] [Related]
54. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
Zak M; Yuen PW; Liu X; Patel S; Sampath D; Oeh J; Liederer BM; Wang W; O'Brien T; Xiao Y; Skelton N; Hua R; Sodhi J; Wang Y; Zhang L; Zhao G; Zheng X; Ho YC; Bair KW; Dragovich PS
J Med Chem; 2016 Sep; 59(18):8345-68. PubMed ID: 27541271
[TBL] [Abstract][Full Text] [Related]
55. Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Feng J; Yan PF; Zhao HY; Zhang FC; Zhao WH; Feng M
Biomed Res Int; 2016; 2016():1450843. PubMed ID: 28097126
[TBL] [Abstract][Full Text] [Related]
56. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
[TBL] [Abstract][Full Text] [Related]
57. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
[TBL] [Abstract][Full Text] [Related]
58. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
Xu TY; Zhang SL; Dong GQ; Liu XZ; Wang X; Lv XQ; Qian QJ; Zhang RY; Sheng CQ; Miao CY
Sci Rep; 2015 Jun; 5():10043. PubMed ID: 26040985
[TBL] [Abstract][Full Text] [Related]
59. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
60. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Chen H; Wang S; Zhang H; Nice EC; Huang C
Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
